New scanner could detect brain tumours in world-first
Scientists in Scotland have developed a pioneering new scanner aimed at improving treatment for glioblastoma, the most common and aggressive type of brain tumour.
Field Cycling Imaging (FCI), a new technology derived from MRI, will be used by researchers at the University of Aberdeen and NHS Grampian after receiving £350,000 in funding from the Scottish Government.
This unique scanner can track brain cancer spread by generating detailed images, working at low magnetic fields and detecting tumours without the need for injected dye.
It is hoped FCI will differentiate between tumour growth and "pseudo-progression," allowing for more effective chemotherapy adjustments and preventing premature cessation of treatment.
The technology aims to provide more accurate information for patients and clinicians, potentially improving quality of life, treatment effectiveness, and healthcare cost-effectiveness for glioblastoma patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
5 hours ago
- The Independent
Weight loss jab could be used to treat migraines
Weight loss jabs could cut the number of migraines sufferers experience by half, research suggests. The drugs, similar to Ozempic and Wegovy, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. Researchers have discovered, GLP-1 drug liraglutide, commonly used to treat diabetes, has the potential to significantly reduce migraine frequency. Migraines affect approximately 6 million people in the UK, according to the NHS. Attacks can last for three days causing pain, nausea, vomiting, dizziness and sensitivity to light, sound and smells. Researchers at the Headache Centre of the University of Naples gave 26 adults with obesity and chronic migraines the drug liraglutide. The study presented at the European Academy of Neurology (EAN) Congress 2025, found those who had the drug reported an average of 11 fewer headache days per month. Participants also experienced meaningful improvements in quality of life, work, study, and social functioning within just two weeks of taking the drug. 'Most patients felt better within the first two weeks and reported quality of life improved significantly', said lead researcher Dr Simone Braca. 'The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant.' Growing evidence has linked subtle increases in intracranial pressure to migraine attacks. It's caused by a rise in the pressure of cerebrospinal fluid – which surrounds the brain and spinal cord. This increase in pressure can happen because of a severe head injury, stroke, a brain tumour or high blood pressure. But GLP-1-receptor agonists such as liraglutide reduce cerebrospinal fluid secretion and have already proved effective in treating idiopathic intracranial hypertension (IIH). Patients in the study were screened to exclude papilledema (optic disc swelling resulting from increased intracranial pressure) and sixth nerve palsy, ruling out IIH. Dr Braca and colleagues believe GLP-1 drugs may reduce the release of CGRP (calcitonin gene-related peptide), a key molecule behind migraines. 'We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide', Dr Braca said. 'That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway.' Given liraglutide's established use in type 2 diabetes and obesity, it may represent a promising case of drug repurposing in neurology, study authors said.
The Sun
7 hours ago
- The Sun
Sex drug Viagra has surprising new health benefit and could help 3 million ageing Brits, say scientists
SEX aid pill Viagra helps stiffen your skeleton, a study suggests. The little blue tablet was found to increase production of vital bone cells — so could one day prevent back pain and fractures in old age. Researchers found sildenafil, which is branded as Viagra, helped human stem cells transform into osteoblasts, the bone-building cells. These are vital as the human skeleton regenerates and is completely replaced roughly once every ten years. As we age, we lose more bone than we build, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. The Peking University team's follow-up tests on mice also suggested sildenafil would prevent bone loss. Dr Menglong Hu and Dr Likun Wu said: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' More than three million Britons suffer osteoporosis. Other treatments exist but the researchers said it would be handy to have more cheap and readily available drugs. They said: 'Any new drug must be evaluated. This is time-consuming, expensive and risky. But sildenafil is approved and safe.' Viagra was invented as a heart drug in the 1980s before it was found to help with erectile dysfunction. Studies have since suggested it might also reduce dementia risk. Why You Should Think Twice Before Popping Viagra Just For Fun (1)
Telegraph
8 hours ago
- Telegraph
Sir Ian McGeechan: Cancer treatment has worked
Sir Ian McGeechan has given a positive update on his cancer diagnosis, saying 'the treatment has worked'. The British and Irish Lions legend revealed he had been diagnosed with prostate cancer in an interview with Telegraph Sport last month. The Scot, who was Lions head coach for four tours, said then that he had undergone six weeks of radiotherapy treatment, and would have to wait another six weeks to discover whether it had been successful. Speaking to fellow Telegraph columnist Will Greenwood during Sky Sports' coverage of the opening Lions game against Argentina, McGeechan revealed he had since received good news about the condition. Asked about his health, McGeechan answered: 'All good, thank you, the treatment has worked. Fine.' Host Alex Payne added: 'So glad to hear that Geech has had the all clear'. McGeechan is perhaps the ultimate Lions legend after his unparalleled career both as a player and coach. The 78-year-old was inundated with messages after his Telegraph interview, with the game of rugby uniting to wish him well. McGeechan has been coaching at Doncaster Knights as he maintains his illustrious career in the game, some 51 years after he first went on a Lions tour as a player in 1974, before being selected again in 1977. McGeechan was then head coach in 1989, 1993, 1997 and 2009, as well as coach of the midweek side in 2005. When revealing his cancer diagnosis, McGeechan said he hoped his honesty would inspire others to get tested. 'I don't want to make a big thing of it, but it is important to get the message out about urging people to get tested,' he said. 'I said that to our players here. I said to them that they make sure they get themselves tested. If you are younger, it is more important. 'Hopefully this interview can be educational. What I would say to people is don't back off it. It is a blood test, it is not what you always think. Just get it done. I have good people looking after me. It is the very good side of the NHS. The staff of the Bexley Cancer Wing at St James's Hospital in Leeds have been brilliant. 'When I had my last treatment, from the receptionist to the radiographer, they all said: 'Well done, good luck, have a happy time.' Everyone. They all knew. When they are looking up your details and you are going on to your next step, it says which number of treatment is it, and it is what they say to every person when they get to their last treatment, which I think is great. That support and the environment is so positive. What will be, will be.'
